-

Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier for pharmaceutical and biotech companies to connect real-world data with clinical research—helping them generate stronger evidence, faster.

Thermo Fisher’s PPD™ clinical research business and Datavant will enable secure connection and analysis of real-world data (RWD), spanning RWD enrichment of randomized clinical trials, PPD™ CorEvitas™ Clinical Registries and PPD™ Evidera™ solutions.

Datavant enables privacy-preserving tokenization and linkage of patient-level data across more than 350 RWD partners and 80,000 U.S. hospitals and clinics. With this technology, Thermo Fisher’s PPD clinical research business can securely connect de-identified research datasets and retrieve consented electronic medical record (EMR) data for bespoke RWD generation. Integrating Datavant’s encrypted token technology within Thermo Fisher’s RWD infrastructure will provide biopharmaceutical and biotech customers with access to enhanced linked patient data and advanced analytics to design more connected studies, improve recruitment and accelerate evidence generation, ultimately supporting better patient outcomes.

The collaboration builds on Thermo Fisher’s broader investments in digital innovation, including its strategic collaboration with OpenAI, to deliver more value and greater scientific innovation to life sciences customers.

“Data interoperability is critical to the next generation of evidence generation,” said Karen Kaucic, M.D., president, patient and advisory services, and chief medical officer, clinical research, Thermo Fisher Scientific. “By enabling privacy-protected data connectivity at scale, this collaboration allows us to deliver a more seamless and efficient research experience for our customers.”

“This collaboration with Thermo Fisher underscores Datavant’s role in enabling secure, privacy-preserving data connectivity at scale,” said Arnaub Chatterjee, GM and President of Life Sciences at Datavant. “By combining Datavant’s trusted data linkage technology with Thermo Fisher’s deep clinical research expertise and infrastructure, we’re helping bring richer, more connected patient data into the research process. Reducing friction across the research lifecycle – from clinical trials through real-world evidence – is key so that our shared life sciences partners can generate insights faster and advance better outcomes for patients.”

The collaboration strengthens Thermo Fisher’s leadership in RWE, registry, and observational study services, while complementing the company’s ongoing investments in digital innovation aimed at transforming how data and AI are applied across clinical research and development.

“By integrating Datavant’s capabilities with Thermo Fisher’s data, digital and AI capabilities, we can help our customers accelerate insights and ultimately improve patient outcomes,” said Krishna Cheriath, vice president, head of digital and AI, biopharma services, Thermo Fisher Scientific. “This collaboration represents another milestone in our continued investment in digital transformation to accelerate innovation for our customers.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
E-mail: nadine.maeser@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Nadine Maeser
E-mail: nadine.maeser@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that...

Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc...

Thermo Fisher Scientific Announces Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier...
Back to Newsroom